Payment overview · 2025
General Payments
$381.41
11 reported records · 3 companies
Healthcare provider profile · identity verified
Dawn Lee Macfarland, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HUNTINGTON, WV · NPI 1881623155
Verified facts
What the public records show
CMS Open Payments records show Dawn Lee Macfarland, M.D. received $381.41 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 76.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $292.96 | 76.8% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $73.66 | 19.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.79 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $381.41 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $285.25 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $73.66 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $7.71 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $7.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 438 | 53 |
| Alprazolam | Alprazolam | 402 | 48 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 281 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 209 | 25 |
| Gabapentin | Gabapentin | 189 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 170 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 37 |
| Lisinopril | Lisinopril | 118 | 30 |
| Furosemide | Furosemide | 115 | 37 |
| Atorvastatin Calcium | Atorvastatin Calcium | 106 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 28 |
| Omeprazole | Omeprazole | 96 | 31 |
| Diazepam | Diazepam | 92 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 23 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 90 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 20 |
| Montelukast Sodium | Montelukast Sodium | 73 | 22 |
| Losartan Potassium | Losartan Potassium | 71 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 24 |
| Ondansetron Odt | Ondansetron | 70 | 24 |
| Ibuprofen | Ibuprofen | 68 | 22 |
| Famotidine | Famotidine | 67 | 23 |
| Simvastatin | Simvastatin | 66 | 18 |
| Ozempic | Semaglutide | 62 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 17 |
| Potassium Chloride | Potassium Chloride | 61 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 53 | 16 |
| Azithromycin | Azithromycin | 51 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 20 |
| Bupropion Xl | Bupropion Hcl | 50 | 13 |
| Nystatin | Nystatin | 50 | 18 |
| Trazodone Hcl | Trazodone Hcl | 49 | 11 |
| Tramadol Hcl | Tramadol Hcl | 48 | suppressed |
| Clonazepam | Clonazepam | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Prednisone | Prednisone | 41 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 41 | 11 |
| Metformin Hcl | Metformin Hcl | 40 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Eliquis | Apixaban | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 23 |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Carvedilol | Carvedilol | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 14 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 12 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $381.41 · 11 records | ABBVIE INC. | AIRSUPRA, ELIQUIS, QULIPTA, UBRELVY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error